An Observational Study of the Factor Xa Inhibitors Rivaroxaban and Apixaban as Reported to Eight Poison Centers
- 1 February 2016
- journal article
- research article
- Published by Elsevier in Annals of Emergency Medicine
- Vol. 67 (2) , 189-195
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- 2013 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 31st Annual ReportClinical Toxicology, 2014
- Monitoring the anticoagulant effect after a massive rivaroxaban overdoseJournal of Thrombosis and Haemostasis, 2014
- An observational case series of dabigatran and rivaroxaban exposures reported to a poison control systemThe American Journal of Emergency Medicine, 2014
- Dabigatran: how the drug company withheld important analysesBMJ, 2014
- Massive human rivaroxaban overdoseThrombosis and Haemostasis, 2014
- Laboratory testing of rivaroxaban in routine clinical practice: When, how, and which assaysAnnals of Medicine, 2013
- Efficacy and Toxicity of Factor Xa InhibitorsJournal of Pharmacy & Pharmaceutical Sciences, 2013
- Reversal of antithrombotic agentsAmerican Journal of Hematology, 2012
- Evaluation of Prothrombin Complex Concentrate and Recombinant Activated Factor VII to Reverse Rivaroxaban in a Rabbit ModelAnesthesiology, 2012
- Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjectsCurrent Medical Research and Opinion, 2008